Our Mission
To cure cancers and prevent infectious diseases through therapeutic, prophylactic and personalized vaccination.
ADVANCING HEALTHCARE
WITH LENTIVIRAL VECTORS
Lentiviral vectors have the power to cure and prevent major infectious diseases and cancers; revolutionizing global healthcare and the immunotherapy sector.
Our preclinical and proof-of-concept studies have shown very promising results for preventive and therapeutic vaccines based on our technology platform.
We have a large portfolio of candidates for clinical development.
To support the development of our proprietary lentiviral vector platform, we actively collaborate with academic and industrial partners in Europe, North America and China.
CLINICAL DEVELOPMENT
Given the exceptional quality of our preclinical results, we aim to revolutionize immunotherapy and demonstrate the efficacy of our technology platform through clinical trials, either directly or via collaboration.
In this context, we have launched a Phase I/IIa clinical trial in the United States on papillomavirus-induced cancers.
At the same time, an exploratory trial on hepatitis B has been launched in partnership with Shanghai Jinwei Biotechnology, our partner in China, with extremely promising initial results.
Through our lentiviral technology that has numerous applications, we can become the leading developer of therapeutic and prophylactic vaccination.
